Regenerative Medical Technology (RMTG) Gross Margin (2018 - 2026)
Regenerative Medical Technology (RMTG) posted quarterly Gross Margin of 66.93% for Q1 2026, down 225.0% year-over-year from 53.54% in Q1 2025, and up 34.97% quarter-over-quarter from 49.59% in Q4 2025.
Regenerative Medical Technology (RMTG) Gross Margin (2018 - 2026) Analysis & Trends
Regenerative Medical Technology's Gross Margin history runs 9 years deep, the most recent figure standing at 66.93% for Q1 2026.
- In Q1 2026, Gross Margin fell 225.0% year-over-year to 66.93%; the TTM figure through Mar 2026 stood at 56.99% (down 1171.0% YoY), while the FY2025 annual figure was 55.11%, down 1362.0% from the prior year.
- Gross Margin for Q1 2026 stood at 66.93%, up from 49.59% in the prior quarter.
- The five-year high for Gross Margin was 75.74% in Q3 2024, with the low at 35.57% in Q1 2022.
- The 5-year median for Gross Margin is 66.93% (2026), against an average of 62.56%.
- The sharpest annual moves came in 2022 and 2025: Gross Margin jumped 26845 bps in 2022, then tumbled 3326 bps in 2025.
- Regenerative Medical Technology's Gross Margin stood at 63.37% in 2022, then grew by 11 bps to 70.63% in 2023, then dropped by 8 bps to 64.88% in 2024, then retreated by 24 bps to 49.59% in 2025, then soared by 35 bps to 66.93% in 2026.
- Business Quant data shows RMTG's Gross Margin at 66.93% in Q1 2026, 49.59% in Q4 2025, and 42.49% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.92 Bn | 53.78 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 42.07 Bn | 36.97 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 31.70 Bn | 28.39 Bn | 992.69 Mn | 76.90% |
| 7 | BioNTech SE | 27.99 Bn | 9.60 Bn | 668.28 Mn | 63.27% |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 84.20% |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | - |
| 10 | Regenerative Medical Technology | 829,068.92 | -232,379.08 | 1.77 Mn | 66.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 66.93% |
| Dec 31, 2025 | 49.59% |
| Sep 30, 2025 | 42.49% |
| Jun 30, 2025 | 59.56% |
| Mar 31, 2025 | 69.18% |
| Dec 31, 2024 | 64.88% |
| Sep 30, 2024 | 75.74% |
| Jun 30, 2024 | 66.41% |
| Mar 31, 2024 | 69.64% |
| Dec 31, 2023 | 70.63% |
| Sep 30, 2023 | 69.62% |
| Jun 30, 2023 | 70.24% |
| Mar 31, 2023 | 68.28% |
| Dec 31, 2022 | 63.37% |
| Sep 30, 2022 | 72.05% |
| Jun 30, 2022 | 49.40% |
| Mar 31, 2022 | 35.57% |
| Dec 31, 2021 | 31.69% |
| Sep 30, 2021 | 46.37% |
| Jun 30, 2021 | 24.79% |